Biglia N, Sgro L, Defabiani E, De Rosa G, Ponzone R, Marenco D, Sismondi P
Gynaecological Oncology Unit, Institute for Cancer Research and Treatment (IRCC) of Candiolo and Mauriziano Umberto I Hospital, University of Turin, Largo Turati 62, 10128 Turin, Italy.
Eur J Surg Oncol. 2005 Jun;31(5):467-72. doi: 10.1016/j.ejso.2005.02.005.
To assess whether the pathological characteristics of breast carcinomas arising in post-menopausal women who ever used hormonal replacement therapy (HRT) differ from those of post-menopausal patients who never used HRT.
Six hundred and forty three consecutive breast cancer patients were entered in a case control-study. Cases were represented by 111 breast cancer patients who had used or were using HRT at the time of diagnosis, while the remaining 532 patients who never used HRT were chosen as controls.
Tumour diameter was smaller in HRT users (17.6 vs 22.1 mm; p=0.002) and tumours of lobular histology were almost twice more frequent among HRT users as in 'never users' (21 vs 12%; p=0.01). No differences were found in grading, hormonal receptor status and axillary nodal status. The expression of c-erb B-2, p53, Ki67 and PS2 measured by immunohistochemistry was similar in the two groups.
Our findings suggest that HRT use may modify the pathological presentation of breast cancer. Further studies are indicated, while other clinical-pathological characteristics did not differ according to HRT use.
评估曾经使用激素替代疗法(HRT)的绝经后女性所患乳腺癌的病理特征是否与从未使用HRT的绝经后患者不同。
643例连续的乳腺癌患者进入病例对照研究。病例组为111例在诊断时曾使用或正在使用HRT的乳腺癌患者,其余532例从未使用HRT的患者作为对照组。
HRT使用者的肿瘤直径较小(17.6对22.1mm;p=0.002),小叶组织学肿瘤在HRT使用者中的发生率几乎是“从未使用者”的两倍(21%对12%;p=0.01)。在分级、激素受体状态和腋窝淋巴结状态方面未发现差异。通过免疫组织化学检测的c-erb B-2、p53、Ki67和PS2的表达在两组中相似。
我们的研究结果表明,使用HRT可能会改变乳腺癌的病理表现。需要进一步研究,而其他临床病理特征根据HRT使用情况并无差异。